Literature DB >> 708645

Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity.

C Hershko, G Graham, G W Bates, E A Rachmilewitz.   

Abstract

Iron binding in the sera of 35 patients with beta thalassaemia major and intermedia was studied. In patients receiving regular blood transfusions since infancy transferrin was completely saturated and about 2.7--7.1 mumol/l of the serum iron could be removed by dialysis or ultrafiltration in the presence of a chelating agent or by filtration on DEAE-Sephadex-catecholdisulphonic acid columns. In contrast, less than 1.0 mumol/l of transferrin bound iron was removed when subjected to the same procedures. The non-specific iron of thalassaemic sera could no longer be demonstrated after incubation with normal serum. These findings indicate that non-specific iron is a chelatable with normal serum. These findings indicate that non-specific iron is a chelatable compound which is readily available for transferrin binding. In view of the known toxicity of unbound iron, its identification in thalassaemic sera might be of relevance to the pathogenesis of tissue damage and the protective effect of iron chelating therapy in this disease.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 708645     DOI: 10.1111/j.1365-2141.1978.tb03662.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  79 in total

Review 1.  β-thalassemia intermedia: a clinical perspective.

Authors:  Khaled M Musallam; Ali T Taher; Eliezer A Rachmilewitz
Journal:  Cold Spring Harb Perspect Med       Date:  2012-07       Impact factor: 6.915

2.  Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders.

Authors:  Louise de Swart; Jan C M Hendriks; Lisa N van der Vorm; Z Ioav Cabantchik; Patricia J Evans; Eldad A Hod; Gary M Brittenham; Yael Furman; Boguslaw Wojczyk; Mirian C H Janssen; John B Porter; Vera E J M Mattijssen; Bart J Biemond; Marius A MacKenzie; Raffaella Origa; Renzo Galanello; Robert C Hider; Dorine W Swinkels
Journal:  Haematologica       Date:  2015-09-18       Impact factor: 9.941

3.  CD1 Mouse Retina Is Shielded From Iron Overload Caused by a High Iron Diet.

Authors:  Devang L Bhoiwala; Ying Song; Alyssa Cwanger; Esther Clark; Liang-liang Zhao; Chenguang Wang; Yafeng Li; Delu Song; Joshua L Dunaief
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-08       Impact factor: 4.799

Review 4.  The long history of iron in the Universe and in health and disease.

Authors:  Alex D Sheftel; Anne B Mason; Prem Ponka
Journal:  Biochim Biophys Acta       Date:  2011-08-09

5.  Efficient clearance of non-transferrin-bound iron by rat liver. Implications for hepatic iron loading in iron overload states.

Authors:  P Brissot; T L Wright; W L Ma; R A Weisiger
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

6.  Basal endocrine status in African dietary iron overload.

Authors:  Lynette McNamara; Vanessa R Panz; Frederick J Raal; Janice Paiker; Barry I Joffe; Victor R Gordeuk; A Patrick MacPhail
Journal:  Endocrine       Date:  2003-08       Impact factor: 3.633

7.  Hemochromatosis: a model of metal-related human toxicosis.

Authors:  Pierre Brissot; Thibault Cavey; Martine Ropert; François Gaboriau; Olivier Loréal
Journal:  Environ Sci Pollut Res Int       Date:  2016-09-15       Impact factor: 4.223

8.  Safety and efficacy of deferasirox in the management of transfusion-dependent patients with myelodysplastic syndrome and aplastic anaemia: a perspective review.

Authors:  Rebecca L C Adams; Robert J Bird
Journal:  Ther Adv Hematol       Date:  2013-04

9.  Iron overload in sickle cell disease.

Authors:  Radha Raghupathy; Deepa Manwani; Jane A Little
Journal:  Adv Hematol       Date:  2010-05-17

10.  Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia.

Authors:  Shahina Daar; Anil Pathare; Hanspeter Nick; Ulrike Kriemler-Krahn; Abdel Hmissi; Dany Habr; Ali Taher
Journal:  Eur J Haematol       Date:  2008-12-22       Impact factor: 2.997

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.